

## Daftar Kepustakaan

1. Presti JC . Neoplasma in prostate gland . in McAninchh JW, Lue TF (eds). Smith and Tanagho's General Urology . 16<sup>th</sup> ed . New York : Lange Medical Book/McGraw-Hill; 2003 . p. 267-276 .
2. Lepor, Herbert . Alpha-blockers for the treatment of benign prostatic hyperplasia . Urologic Clinics of North America . 2016;43(3):311–23 .
3. Skinder D, Zacharia I, Studin J, Covino J . Benign prostatic hyperplasia . Journal of the American Academy of Physician Assistants . 2016;29(9):19-23 .
4. Suryawisesa, Malawat, Bustam . Hubungan faktor geografis terhadap skor gejala prostat internasional (IPSS) pada komunitas suku makassar usia lanjut tahun 1998 . Ropanasuri Journal of Surgery . 2010;5:212-218 .
5. Mochtar CA, Umbas R, Soebadi DM, Rasyid N, Noegroho BS, et al . Panduan penatalaksanaan klinis pembesaran prostat jinak (Benign Prostatic Hyperplasia/BPH) . Indonesia: Ikatan Ahli Urologi Indonesia (IAUI); 2017 .
6. Amalia, Rizki . Faktor-faktor risiko terjadinya pembesaran prostat jinak . Semarang : Fakultas Kedokteran Universitas Diponegoro; 12 Februari 2008 . <http://eprints.undip.ac.id/19133/> .
7. Fitriana N, Zuhirman, Suryanto . Hubungan benign prostate hypertrophy dengan disfungsi ereksi di rsud arifin achmad provinsi riau . Pekanbaru : Fakultas Kedokteran Universitas Riau; Januari 2014 . <https://jom.unri.ac.id/index.php/JOMFDOK/article/view/2919> .
8. Lepor, Herbert . The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia . U.S. National Library of Medicine . 2006;8(4):s3-s9 .
9. Lowe, Franklin C . Role of the newer alpha<sub>1</sub>-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms . Clinical Therapeutics . 2004;26(11):1701-1713 .
10. Schoenfeld MJ, Shotidge EF, Gelwicks SC, Cui Z, Wong DG . Treatment patterns in alpha-blocker therapy for benign prostatic hyperplasia . American Journal of Men's Health . May 2014;4(3):267-272 .
11. Lowe FC . Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect . Clinical Therapeutics . 1997;19:730–742 .

12. Chapple, Christopher R . A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms . U.S. National Library of Medicine . 2005;7(4):s22-s30 .
13. Barry MJ, McVary KT, Gonzales CM, Wei JT, Roehrborn CG, et al . AUA guideline on management of benign prostate hyperplasia . The Journal of Urology . 2011 . Vol. 185 .
14. Lepor H, Lowe FC . Evaluation and nonsurgical management of benign prostatic hyperplasia . Campbell's Urology . 8<sup>th</sup> ed . Philadelphia : Saunders; 2002 . p. 1337-1378 .
15. Park YW, Lee JH . Correlation between the visual prostate symptom score and international prostate symptom score in patients with lower urinary tract symptoms . International Neurourology Journal . 2014;18:37-41 .
16. Barry MJ, Fowler FJ, O'Leary MP, et al . The american urological association symptom index for benign prostatic hyperplasia . The Journal of Urology . February 2017;197(2S):S189-S197 .
17. Liu CC, Wang CJ, Huang SP, Chou YH, et al . Relationships between american urological association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia . The Kaohsiung Journal of Medical Science . Juni 2004;20(6):273-278 .
18. Kapoor A . A benign prostatic hyperplasia ( BPH ) management in primary care setting . The Canadian Journal of Urology . Oktober 2012;19(1):10-17 .
19. Tanagho EA . Anatomy of the genitourinary tract . In McAninchh JW, Lue TF (eds) . Smith and Tanagho's General Urology . 16<sup>th</sup> ed . New York : Lange Medical Book/McGraw-Hill; 2003 . p. 4-16 .
20. Paulsen F, Waschke J . Sobotta - atlas of human anatomy . 15<sup>th</sup> Ed . Vol. 2 Philadelphia: Urban & Fischer; 2012 . p. 189 .
21. Gartner LP, Hiatt JL . Color Atlas and Text of Histology . 6<sup>th</sup> Ed . Philadelphia : Elsevier Saunders; 2014 . p. 437 .
22. Eroschenko, Victor P . diFiore's atlas of histology with functional correlations . 12<sup>th</sup> ed . Idaho: Lippincott Williams & Wilkins; 2013 . p. 477-501 .
23. Guyton AC, Hall JH . Guyton and hall textbook of medical physiology . 11<sup>th</sup> ed . Philadelphia: Elsevier Saunders; 2005 . p. 996-1000 .

24. Parsons KJ . Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factor . U.S. National Library of Medicine . 2010;5:212-218 .
25. Adelia F, Monoarfa A, Wagiu A . Gambaran benigna prostat hiperplasia di rsup prof. dr. r. d. kandou periode januari 2014 - juli 2017 . Manado : Fakultas Kedokteran Universitas Sam Ratulangi; 2017 .  
<https://ejournal.unsrat.ac.id/index.php/eclinic/article/view/18538/18065> .
26. Roehrborn CG, McConnell JD . Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia . Campbell's Urology . 8<sup>th</sup> ed . Philadelphia: Saunders; 2002 . p. 1297-1336 .
27. Mathur RP, Nayak S, Sivaramakrishnan R, Jain V . Role of alpha-blocker in hypertension with benign prostatic hyperplasia . Journal of the Association of Physicians of India . September 2014;62:40-44 .
28. Wei JT, Calhoun E, Jacobsen SJ . Urologic diseases in America Project: benign prostatic hyperplasia . The Journal of Urology . 2005;173:1256-1261 .
29. Gravas S, Bachmann A, Descazeaud A, et al . Guidline on the management of non-neurogenic male lower urinary tract symptoms ( LUTS ), incl. benign prostatic obstruction (BPO) . European Association of Urology; 2014 .
30. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al . Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the american urological association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients . The Journal of Urology . 1995;154:1770-4 .
31. Kilic M, Ozdemir A, Altinova S, et al . What is the best radiological method to predict the actual weight of the prostate? . Turkish Journal of Medical Science . 2014;44:31-35 .
32. Abrams P, Chapple C, Khoury S, et al . Evaluation and treatment of lower urinary tract symptoms in older men . The Journal of Urology . 2013;189(1):S93-S101 .
33. Lepor, Herbert . The role of alpha blockade in the treatment of BPH . In: Lepor H, Lawson RK, eds. Prostatic Diseases . Philadelphia, PA: WB Saunders; 1973: 170–181 .
34. Sica DA . Alpha<sub>1</sub>-adrenergic blockers: current usage considerations . The Journal of Clinical hypertension . December 2005;7(12):757-762 .

35. Narayan P, Tewari A . A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia . *The Journal of Urology* . 1998;160:1701-1706 .
36. Neill MG, Shahani R, Zlotta AR . Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy . *Therapeutics and Clinical Risk Management* . Dove Medical Press . 2008;4(1):11-18 .
37. Troost J, Tatami S, Tsuda Y, Mattheus M, et al . Effect of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin . *British Journal of Clinical Pharmacology* . 2011;72(2):247-256 .
38. Oesterling JE . Benign prostatic hyperplasia: medical and minimally invasive treatment options . *The New England Journal of Medicine* . 1995; 332: 99-109 .
39. Setthawong V, Mahawong P, Pattanachindakun N, et al . To investigate the correlation between the visual prostate symptom score, the international prostate symptom score, and uroflowmetry parameters in adult thai males of different educational levels . *Prostate International* . 2018;30: 1-4 .
40. Roy A, Singh A, Sidhu DS, et al . New visual prostate symptom score versus international prostate symptom score in men with lower urinary tract symptoms: a prospective comparison in indian rural population . *Nigerian Journal of Surgery* . 2016;22:111-117 .
41. Monoarfa, RA . Validasi international prostate symptom score versi bahasa Indonesia . Jakarta: Fakultas Kedokteran Universitas Indonesia; Desember 2012 . <http://juri.urologi.or.id/index.php/juri/article/view/20> .
42. Lemeshow S, Hosmer DW, Klar J, Lwanga SK . Adequacy of sample size in health studies . World Health Organization : 1990 .
43. Mandang CS, Monoarfa RA, Salem B . Hubungan antara skor IPSS dengan quality of life pada pasien BPH dengan LUTS yang berobat di poli bedah rsup prof. dr. r. d. kandou manado. Manado: Fakultas Kedokteran Universitas Sam Ratulangi; April 2015 . <https://ejournal.unsrat.ac.id/index.php/eclinic/article/view/7481> .
44. Ikuero SO, Akindiji YO, Akinoso OA, et al . Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in nigerian men. *Urologia Internationalis* . 2008;80(3):296-9 .

45. Boyle P, Napalkov P . The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension . Scandinavian Journal of Urology and Nephrology . 1995;168:7–12 .
46. Poyhonen A, Hakkinen JK, Koskimaki J, et al . Empirical evaluation of grouping of lower urinary tract symptoms : principal component analysis of tampere ageing male urological study data . BJU International . 2012;111:467-473 .
47. Levin, R. M. et al . Obstructive response of human bladder to BPH versus rabbit bladder response to partial outlet obstruction: a direct comparison . Neurourology and Urodynamics Journal . 2000;19:609–629.
48. Yamanishi T, Tatsumiya K, Furuya N, et al . Long-term efficacy of tamsulosin in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in real-life practice . UroToday International Journal . February 2009 . Vol. 2 .
49. Lojanapiwat B, Pempongkosol S . The efficacy and safety of oral tamsulosin controlled absorption system ( OCAS ) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study . International Brazilian Journal of Urology . 2011;37(4):468-476 .
50. Suzuki H, Yano M, Awa Y, et al . Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and rand medical outcomes study 36-item health survey . International Journal of Urology . 2006;13:1202-1206 .

